FIELD: medicine.
SUBSTANCE: invention relates to medicine and is intended to predict the development of metastases in patients with breast cancer (BC) based on the analysis of the expression of the MAGEA2, MAGEB1 and XAGE3 genes. Amplification is performed in real time in the presence of EvaGreen Dye using highly specific primers for the MAGEA2, MAGEB1, XAGE3 and GAPDH genes, primary data are analyzed using an amplifier software; relative expression of genetic loci is calculated using formula 2-ΔCt, the expression ratio of genes is calculated – KMAGEA2, KMAGEB1, KXAGE3 according to the formula K=Ecancer/Enormal, where Ecancer – relative gene expression in tumor tissue, Enormal – relative gene expression of normal breast tissue, and with values KMAGEA2<0.6±0.2, KMAGEB1<1.0±0.3 and KXAGE3<1.0±0.8 the absence of metastases is predicted, and when the values of KMAGEA2>3.5±0.9, KMAGEB1>17.7±2.1 and KXAGE3>14.7±1.5 the development of metastases is predicted.
EFFECT: method allows to forecast the development of metastases in breast cancer.
1 cl, 1 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PREDICTION OF LIVER METASTASES IN PATIENTS WITH COLON CANCER | 2018 |
|
RU2686687C1 |
| METHOD FOR PREDICTION OF DEVELOPING METASTASES IN UTERINE CANCER PATIENTS BASED ON ANALYSIS OF MAGEA1, MAGEB2 AND PRAME1 GENE EXPRESSION | 2018 |
|
RU2698895C1 |
| METHOD FOR PREDICTING THE DEGREE OF RISK OF DEVELOPING HEMATOGENOUS METASTASES IN INVASIVE CARCINOMA OF A NON-SPECIFIC TYPE OF MAMMARY GLAND BASED ON THE ASSESSMENT OF THE EXPRESSION OF LIMCH1 PROTEIN | 2020 |
|
RU2755242C1 |
| METHOD FOR PREDICTING RISK OF BREAST CANCER PROGRESSION WITH UNDERLYING TAMOXIFEN TAKING INTO ACCOUNT EXPRESSION CHARACTERISTICS OF TUMOUR | 2023 |
|
RU2823488C1 |
| METHOD FOR PREDICTING THE DEVELOPMENT OF METASTASES IN REGIONAL LYMPH NODES IN PATIENTS WITH GASTRIC ADENOCARCINOMA | 2017 |
|
RU2661600C1 |
| METHOD FOR PREDICTING NON-METASTATIC SURVIVAL IN PATIENTS WITH BREAST CANCER ON THE BASIS OF EXPRESSION OF SOMATIC-STEM TRANSITION GENES IN RESIDUAL TUMOR AFTER PRE-OPERATIVE TREATMENT | 2018 |
|
RU2682879C1 |
| TEST-SYSTEM FOR PREDICTION OF RELAPSE DEVELOPMENT IN PATIENTS WITH UTERINE CORPUS CANCER BASED ON EXPRESSION LEVEL OF THE ESR1 GENE | 2017 |
|
RU2661599C1 |
| METHOD FOR PREDICTION OF METASTASES DEVELOPMENT IN PATIENTS WITH GASTRIC CANCER | 2016 |
|
RU2624505C1 |
| METHOD FOR PREDICTION OF ENDOMETRIAL CANCER PATIENTS SURVIVAL ON THE BASIS OF THE ESR1 GENE EXPRESSION LEVEL | 2015 |
|
RU2611352C1 |
| METHOD OF RECURRENT ENDOMETRIAL CANCER PREDICTION BASED ON PTEN AND CYP1B1 GENES EXPRESSION LEVEL | 2015 |
|
RU2605302C1 |
